Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NovoCure Limited    NVCR   JE00BYSS4X48

NOVOCURE LIMITED

(NVCR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/06/2020 07/07/2020 07/08/2020 07/09/2020 07/10/2020 Date
62.86(c) 59.58(c) 60.97(c) 60.07(c) 60.38(c) Last
796 727 680 510 856 364 412 821 270 310 Volume
+3.64% -5.22% +2.33% -1.48% +0.52% Change
More quotes
Financials (USD)
Sales 2020 436 M - -
Net income 2020 13,0 M - -
Net cash position 2020 137 M - -
P/E ratio 2020 639x
Yield 2020 -
Sales 2021 534 M - -
Net income 2021 46,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 140x
Yield 2021 -
Capitalization 6 065 M 6 065 M -
EV / Sales 2020 13,6x
Capi. / Sales 2021 11,3x
Nbr of Employees 782
Free-Float 83,4%
More Financials
Company
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through... 
More about the company
Surperformance© ratings of NovoCure Limited
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVOCURE LIMITED
07/08NOVOCURE : Announces Over 100 Physicians in the U.S. Now Certified to Prescribe ..
BU
07/07NOVOCURE : Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields ..
BU
07/01NOVOCURE : to Report Second Quarter 2020 Financial Results
BU
06/02NOVOCURE : Announces Launch of MyLink™ to Enable Patient-Guided, Remote Do..
BU
04/30NOVOCURE : Reports First Quarter 2020 Financial Results and Provides Company Upd..
BU
04/27NOVOCURE : Announces Presentation of EF-19 Post-approval Registry Trial Data Stu..
BU
04/03NOVOCURE : Provides Business Update Related to COVID-19
BU
03/30NOVOCURE : ® response to COVID-19
PU
03/20NOVOCURE : German Federal Joint Committee Updates Medical Care Directive to incl..
BU
03/19NOVOCURE : Announces Optune Lua™ as the Brand Name for the NovoTTF-100L&tr..
BU
03/12NOVOCURE : Preclinical Data Show Tumor Treating Fields Induces Immunogenic Cell ..
BU
02/27NOVOCURE : Reports Fourth Quarter and Full Year 2019 Financial Results and Provi..
BU
01/27Virus Hits Hong Kong as Economy Is Still Catching Its Breath After Unrest -- ..
DJ
01/21NOVOCURE : Announces National Reimbursement in Israel for Optune® in Combination..
BU
01/13NOVOCURE : Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues ..
BU
More news
News in other languages on NOVOCURE LIMITED
07/08NOVOCURE : Announces Over 100 Physicians in the U.S. Now Certified to Prescribe ..
07/07NOVOCURE : Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields ..
07/01NOVOCURE : to Report Second Quarter 2020 Financial Results
06/02NOVOCURE : Announces Launch of MyLink™ to Enable Patient-Guided, Remote Do..
04/30NOVOCURE : Reports First Quarter 2020 Financial Results and Provides Company Upd..
More news
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | NVCR | JE00BYSS4X48 | MarketScreener
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 78,57 $
Last Close Price 60,38 $
Spread / Highest target 49,1%
Spread / Average Target 30,1%
Spread / Lowest Target -0,63%
EPS Revisions
Managers
NameTitle
Asaf Danziger Chief Executive Officer & Director
William F. Doyle Executive Chairman
Michael J. Ambrogi Chief Operating Officer
Wilhelmus Groenhuysen Chief Financial Officer
Uri Weinberg Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
NOVOCURE LIMITED-28.35%6 065
ABBOTT LABORATORIES7.11%164 573
MASIMO CORPORATION46.23%12 508
ASAHI INTECC CO., LTD.-6.25%7 320
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.95.28%5 682
GETINGE AB2.13%5 271